Citations

Clear

128 citation(s) found for "Jena, A".

Global Burden of Elevated LDL-C
Collaborators, GBD 2023 LDL Cholesterol, Razo, Christian, DeCleene, Nicole K., Johnson, Catherine O., Stark, Benjamin, LeGrand, Kate, Aalruz, Hasan, Abaraogu, Ukachukwu O., Abdelnabi, Mahmoud, Abd-Elsalam, Sherief, Abdelwahab, Siddig Ibrahim, Abdollahi, Arash, Abdrabou, Mostafa M., Abdul‐Rahman, Toufik , Getahun, Habtamu Abebe, Abiodun, Olumide, Abohashem, Shady, Abonie, Ulric Sena , Abourashed, Nagah M , Abramov, Dmitry, Abrar, Mohammed Mehdi, Farha, Rana Kamal Abu, Abubakar, Bilyaminu, Aburuz, Salahdein, Abushanab, Dina, Adams, Lisa C., Adamu, Nuhu Lawan Lawan, Adegbile, Oluwatobi E , Adegoke, Nurudeen A., Adekola, Saheed Ayodeji, Adeleke, Olumide Thomas , Adesina, Miracle Ayomikun, Afoakwah, Clifford, Afolabi, Aanuoluwapo Adeyimika, Afrashteh, Fatemeh , Afrifa-Yamoah, Ebenezer, Agyemang‐Duah, Williams , Ahmad, Suhaib, Ahmed, Asma , Ahmed, Gasha Salih, Ahmed, Luai A., Ahmed, Mehrunnisha Sharif, Ahmed, Meqdad Saleh , Ahmed, M. , Ahmed, Mushood, Ahmed, Syed Anees, Ahmed, Zohra, Aiyer, Aishwarya, Ajami, Marjan, Akalanka, Kasuni H.M. , Akhtar, Muhammad Nadeem, Akrami, Ashley E, Akyea, Ralph Kwame, Hasan, Syed Mahfuz Al , Zoubi, Mohammad Ahmmad Mahmoud Al, Alahdab, Fares , Al-Ahmad, Mohammad M. , Alajajian, Stephen , Alajlani, Muaaz , Alalwan, Tariq A., Al-Amri, Issa Sulaiman, Alanzi, Turki M., Alarifi, Abdullah, Al-Azzam, Sayer, Albashtawy, Mohammed, Al-Dewik, Nader, Algahtani, Fahad D., Algammal, Abdelazeem M, Alhalaiqa, Fadwa Naji, Ali, Mohammad Daud , Ali, Mohammed Usman, Ali, Rafat, Ali, Syed Shujait, AL-Iede, Montaha, Alipour, Morteza, Al-Jabi, Samah W., Alkhatib, Mayson H. , Allawi, Raad Hatim , Allemailem, Khaled S. , (6837737), Mohammed Z. Allouh, Almahmeed, Wael, Al-Marwani, Sabah , Almazan, Joseph Uy, Alnaeem, Mohmmad Minwer, Alotaibi, Haifa F. F., Alqahtani, Saleh A, Alqudah, Mohammad , Alqudimat, Mohammad R, Al-Qudimat, Ahmad Rajeh, Alrimawi, Intima , Alrousan, Sahel Majed, Alshahrani, Najim Z., Altaany, Zaid, Altaf, Awais, Althobiani, Malik A., Altwalbeh, Diala, Al-Worafi, Yaser Mohammed, Aly, Hany, Alzoubi, Karem H., Al-Zubairi, Adel S., Amafah, Joy, Mohammadi, Masoud Aman, Amini, Saeed, Amini-Salehi, Ehsan, Ananda, Roshan A., Ancuceanu, Robert, Anil, Abhishek, Anjana, Prapti, Anuoluwa, Boluwatife Stephen, Anvari, Saeid, Anwar, Sumadi Lukman, Anyasodor, Anayochukwu Edward , Appati, Walter, Arafa, Elshaimaa A , Aravkin, Aleksandr Y. , Areda, Demelash, Aregawi, Brhane Berhe, Torre, Jorge Arias de la, Arruda, Gustavo Aires , Asghari-Jafarabadi, Mohammad , Ashraf, Saad , Asare, Bernard Yeboah‐Asiamah , Atac, Omer, Athari, Seyyed Shamsadin, Atorkey, Prince , Aurangzeb, Khursheed, Awan, Usman Ayub , Awol, Kemal Lemnuro Lemnuro, Ayala, Camila Ospina , Ayli, Berrak Itir, Azad, A.K.M., Azzam, Ahmed Y., Babiker, Rasha, Badar, Muhammad, Badran, Alaa Aboelnour, Baghlaf, Khlood K., Balabekova, Marina, Balakrishnan, Senthilkumar , Baltatu, Ovidiu Constantin , Banach, Maciej, Bashir, Muhammad Irfan , Bashir, Shahid, Bashiri, Azadeh, Bastan, Mohammad-Mahdi, Bayat, Mahdis , Behera, Surama Manjari , Belayneh, Melesse, Bello, Abdulrahman Babatunde , Belo, Luís, Bhaskar, Sonu, Bizzozero-Peroni, Bruno, Bogale, Sitotaw Kerie, Bolourinejad, Paria , Bonny, Aimé , Carvajal, Alejandro Botero, Bouaoud, Souad, Britton, Gabrielle, Bustanji, Yasser, Butt, Zahid A., Cao, Yu, Catapano, Alberico L., Cegolon, Luca, Cembranel, Francieli , Chadwick, Joshua , Chau, Lam Duc, Chaudhary, Anis Ahmad, Chen, An-Tian, Chen, Hana, Chen, Haowei , Cheng, Haojin, Cheung, Ka Ching , Chew, Nicholas WS, Chi, Gerald, Cho, William C. S., Chong, Bryan, Chopra, Deepti, Chopra, Shivani , Cicero, Arrigo Francesco Giuseppe, Criqui, Michael H., Cruz-Martins, Natalia, Dahabiyeh, Lina, Khatri, Bishal Dahal , Dalakoti, Mayank, D’Amico, Emanuele, Damtie, Endalamaw Tesfa, Dandona, Lalit , Dandona, Rakhi, D’Anna, Lucio , Danpanichkul, Pojsakorn, Dardas, Latefa Ali , Das, Sayan Kumar, Davletov, Dimash, Dergaa, Ismail, Derseh, Hunegnaw Almaw , Desale, Aragaw Tesfaw, Devanbu, Vinoth Gnana Chellaiyan, Devegowda, Devananda, Dewan, Syed Masudur Rahman, Dhali, Arkadeep , Dhungel, Bibha, Silva, Diana Dias da, Didehvar, Kimia, Ding, Xueting, Do, Thanh Chi, Do, Thao Huynh Phuong, Dohare, Sushil, Dong, Dachuan, D’Oria, Mario, Dorostkar, Fariba, Doshi, Ojas Prakashbhai, Dresse, Menayit Tamrat , Du, Mi, Ebraheim, Lamiaa Labieb Mahmoud, Edeh, Cynthia , Eftekhari, Behrad, Sedeh, Ashkan Eighaei , Ekholuenetale, Michael , Arab, Rabie Adel El , Eldaboush, Ahmed, El-Dahiyat, Faris , Elhoumed, Mohamed, Elmeligy, Omar Abdelsadek Abdou, Elmonem, Mohamed A., Elmoselhi, Adel B., Elnaem, Mohamed Hassan , Eltahawy, Abdelgawad Salah, Etaee, Farshid, Fakhradiyev, Ildar , Fakorede, Sodiq, Farasani, Abdullah , Fareed, Mohammad , Farhana, Aisha, Faris, MoezAlIslam Ezzat Mahmoud, Farsi, Farima , Fatima, Zareen, Fazylov, Timur, Fekadu, Ginenus , Ferreira, Nuno, Fischer, Florian, Fonzo, Marco , Gadanya, Muktar A., Galali, Yaseen, Ganesh, Balasubramanian , Gangachannaiah, Shivaprakash, Gao, Dingwei, Garcia-Azorin, David, Garg, Paarth, Gautam, Rupesh K., Gaye, Bamba , Gebresilassie, Mizan Habtemichael, Gete, Kalab Yigermal , Ghadirian, Fataneh, Ghaffari, Kazem , Ghamkhar, Arin, Gharaibeh, Lobna, Ghasemi, Mohammadreza, Ghimire, Sailaja, Gil, Artyom Urievich, Gilani, Syed Abdullah , Gohari, Kimiya, Gohil, Megha Nishith , Golechha, Mahaveer, Goleij, Pouya , Golmohammadi, Melika , Goyal, Aman, Grada, Ayman, Grover, Ashna , Gu, Long, Gufue, Zenawi Hagos , Guo, Zheng, Gupta, Sapna , Gurgoglione, Filippo Luca, Haghtalab, Arian, Nam, Nguyen Hai, Hailu, Kirubel Tesfaye , Halder, Pritam, Hamdy, Nadia M., Hamidi, Hossein , Hamidi, Samer, Hamoudi, Rifat, Harsini, Sara, Hasnain, Md Saquib , Hassan, Ikrama, Hassan, Nageeb, Hassan, Treska S , Ahmed, Omed Hassan , Hebert, Jeffrey J., Helmy, Yosra A. , Hiraike, Yuta, Holla, Ramesh, Hoseinzadeh, Mehdi, Hostiuc, Mihaela , Hostiuc, Sorin, Hotwani, Priya, Hu, Yifei, Huang, Junjie, Huang, Yu-Song, Hushmandi, Kiavash, Hussein, Dursa, Hussein, Mohammed Asif , Ibrahim, Ismail A., Ibrayeva, Anel, Ikiroma, Adalia , Ikram, Jibran, Ilic, Irena M., Imam, Mohammad Tarique , Imani, Masoud, Imodoye, Sikiru Opeyemi, Imoh, Lucius Chidiebere , Ionescu, Andreea Iuliana, Ionescu, Radu Tudor, Iqhrammullah, Muhammad, Ishaqui, Azfar Athar, Islek, Duygu , ISMAIL, NAHLAH ELKUDSSIAH, Ismoldayev, Yerlan, Iwagami, Masao , Iyer, Mahalaxmi, Izquierdo-Condoy, Juan S.S., Jafari-Khounigh, Ali , Jahanshahi, Ali, Jahrami, Haitham , Jakovljevic, Mihajlo, Jamal, Armaan, Jamali, Navid, Jamaluddin, Jazlan , Jamshidi, Masoud, Jansen, Robin , Jarrahi, Esmaeil , Javaid, Syed Sarmad , Jawaid, Talha, JEBASINGH, FELIX, Jemal, Mohammed, Ji, Zixiang , Jibat, Nathan T., Jin, Wenyi , Jokar, Mohammad, Joseph, Nitin, Raj, Jesu Vijay Sheldon Joseph Michael, Joshi, Krupal, Joshua, Charity Ehimwenma, Jung, Sang-Hyuk, K, Vaishali, Kadir, Dler Hussein , Kahe, Farima, Kalani, Rizwan, Kalra, Sanjay, Kamenova, Saltanat, Kamorudeen, Ramat T., Kamyshnyi, Oleksandr, Kansal, Subham, Kantar, Rami S., Kar, Debasish , Karakasis, Paschalis, Karimi, Aliasghar, Behnagh, Arman Karimi , Karun, Sadanand , Kazemian, Sina, Kesse-Guyot, Emmanuelle, Khaleel, Anas, Khalid, Nauman, Khalid, Sidra, Khalil, Anees Ahmed , Khan, Ajmal, Khan, Md Abdullah Saeed, Khan, Moien AB, Khan, Muhammad Hamza , Khan, Serab, Khan, Sumaiya, Khan, Yusuf S. , Kheirallah, Khalid A, Khoshvaght, Samira, Khosravi, Sepehr, Kim, Hye Jun, Kim, Kwanghyun, Kisa, Adnan, Kishore, Ladli, Kokkorakis, Michail, Kondybayeva, Aida, Krishan, Kewal, Kua, Chong-Han, Kuddus, Mohammed, Kulimbet, Mukhtar , Kulkarni, Vishnutheertha, Kumar, Dewesh , Kumar, Nitesh, Kumar, Sanjay Kirshan, Kunutsor, Setor K., Kurpad, Krishna Prasad , Kusuma, Dian, Lahariya, Chandrakant, Lai, Daphne Teck Ching , Lai, Hanpeng , Lajunen, Timo, Lakanova, Balzhan, Lallukka, Tea, Larsson, Anders O., Le, Duc Tin , Le, Thao T. , Le, Thoa, Le, Trang Thi Bich , Ledda, Caterina, Lee, Hayeon, Lee, Sang-woong, Lee, Sergey Vadimovich, Lee, Seung Won, Leivaditis, Vasileios, Lema, Gebretsadik Kiros , Lemma, Dawit Alemu, Lenjisa, Jimma, Lewis, Mitchelle Shilpa , Li, Chengfeng , Li, Xingang , Li, Yongze, Lim, Lee-Ling, Lindholm, Daniel , Liu, Haipeng , Liu, Xianliang, Liu, Xuefeng, Liu, Yubo, Livingstone, Katherine M., Llanaj, Erand , Lokunarangoda, Niroshan Chandrajith, López-Gil, José Francisco, Lui, Pauline Po Yee, Luo, Peng, Lv, Lei, Lytvyak, Ellina, Ma, Kevin Sheng-Kai, Mabrok, Mahmoud, Machoy-Rakoczy, Monika , Madinehzad, Seyed Ataollah , Maffia, Pasquale, Gomez, Javier A. Magaña, Mahmood, Nozad Hussein, Malik, Md. Zubbair, Malta, Deborah Carvalho, MAMAND, DOSTE RASHID, Maniya, Muhammad Talha, Mansoor, Farheen, Mansourian, Marjan, Manzoor, Shaista, Marghani, Basma Hamed, Martinez-Piedra, Ramon, Martini, Santi, Martorell, Miquel, März, Winfried, Marzouk, Sammer, Masi, Stefano, Masrouri, Soroush , Maude, Richard J. , Mavrovounis, Georgios, McPhail, Steven M., Mendoza, Walter, Menezes, Ritesh G., Mengistie, Emiru Ayalew, Menon, Tara P., Mestrovic, Tomislav, Mettananda, Chamila Dinushi Kukulege, Metwally, Mohamed M.M., Jonasson, Junmei Miao , Mikrajab, Muhammad Agus Naufal, Minhas, Abdul Mannan Khan, Mirrakhimov, Erkin M., Mitra, Sayan , Mitra, Tridip, Modi, Dhruti, Mohamed, Mona Gamal, Ahmed, Khabab Abbasher Hussien Mohamed, Mohammad, Ameen Mosa , Mohammadi, Saeed, Mohammed, Omer, Mohan, Syam , Molla, Tewodros Shibabaw, Molokhia, Mariam, Moni, Mohammad Ali, Namin, Sara Montazeri , Morovvati, Mahdis, Heris, Reza Mosaddeghi, Motappa, Rohith, Mousavi, Seyed Ahmad , Kiasary, Seyed Mohamad Sadegh Mousavi, Yousefi, Kimia Mozahheb , Mubarik, Sumaira, Munkhsaikhan, Yanjinlkham, Musa, Sani, Mwita, Julius C., Nabipoorashrafi, SeyedAli, Nagarajan, Ahamarshan Jayaraman , Naik, Ganesh R., Naik, Hiten, Nainu, Firzan, Nartey, Yvonne , Nassar, Mahmoud, Natto, Zuhair S., Naureen, Zakira, Nawaiseh, Hala Khaled, Nayak, Biswa Prakash, Nayak, Vinod C., Nazari, Mojdeh, Ndakotsu, Andrew , Nega, Amanuel Tebabal , Nega, Mulata H., Negash, Abigia Ashenafi, Negoi, Ionut, Nguyễn, Cao Duy, Nguyen, Cuong Tat , Nguyen, Hau Thi Hien, Nguyen, Nghia Phu , Nguyen, Phat Tuan , Nguyen, Van Thanh, Niazi, Robina Khan, Nomura, Shuhei , Noreen, Mamoona , Nawsherwan, Noubiap, Jean Jacques, Nugen, Fred, Nur, Aqsha, Odediji, Saheed Adeyinka, Ogunmodede, O.S., Ojedoyin, Olusegun Olatunji , Ojo, Oluwafemi Adeleke , Okati-Aliabad, Hassan, Oliveira, Gláucia Maria Moraes, Olorukooba, Abdulhakeem Abayomi, Ong, Qi Chwen, Orru, H, Ortiz, A., Ortiz-Prado, Esteban, Osborne, Augustus, Osei, George Nkrumah , Ostrominski, John W. , Oumer, Abdu, Ouyahia, Amel, Owolabi, Mayowa O., Oyebola, Kolapo, Ozsahin, Ilker, Anand, Mahesh Padukudru, Palicz, Tamás , Panda, Sujogya Kumar , Pandi-Perumal, Seithikurippu R., Panos, Georgios D., Papadimopoulos, Ilias, Parija, Pragyan Paramita , Parikh, Romil R., Pascucci, Eleonora, Pasovic, Maja , Passera, Roberto, Patel, Mitesh, Patel, Niki Rut, Patel, Satyananda, Patil, Ashlesh, Patil, Shankargouda, Patoulias, Dimitrios, Pattnaik, Snigdha, Toroudi, Hamidreza Pazoki, Pekarcikova, Jarmila, Peprah, Prince, Pereira, Gavin, Pirera, Edoardo , Plotnikov, Evgenii, Poluru, Ramesh, Prasad, Manya, Prashant, Akila, Prates, Elton Junio Sady, Pugliese, Nicola Riccardo, Puvvula, Jagadeesh, Qi, Xiang, Qureshi, Ali, Radhakrishnan, Venkatraman, Raghav, Pankaja, Raghav, Yashpal Singh Raghav, Raghuveer, Pracheth , Rahim, Fakher , Rahim, Hawbash Mohammed-Amin, Rahimi, Sajjad, Rahman, Fryad Majeed, Rahman, M Sajjadur , Rahman, Mohammad Hifz Ur, Rahman, Mosiur, Rajendran, Judah, Rajput, Prashant, Ramasamy, Chitra, Ramasamy, Shakthi Kumaran, Rao, Asad Gul , Rao, Mithun , Rao, Sowmya J, Rasouli-Saravani, Ashkan, Rath, Shree, Rathi, Isha, Rawaf, David Laith , Rawaf, Salman, Reddy, Murali Mohan Rama Krishna, Rezaei, Mina, Rezaei, Nazila, Rezaeian, Mohsen , Rodriguez, Jefferson Antonio Buendia, Roever, Leonardo, Ross, Allen Guy Patrick, Rubeshkumar, Polani, Rwegerera, Godfrey Mutashambara , Saad, Aly M. A., Sabet, Cameron John, Sadarangani, Kabir P., Rafiei, Seyed Kiarash Sadat, Sadeghi, Ehsan, Sadeghi, Erfan, Sadeghi, Masoumeh, Sadek, Bassem, Sadek, Mustafa, Sadr, Hossein, Saeb, Mohammad Reza, Saeed, Umar, Saeedi, Maryam , Safiullah, Muhammad , Sahebkar, Amirhossein, Sajadi, S Mohammad, Saleh, Mohamed A., Salehi, Mahdi , Salimi, Sohrab, Samargandy, Saad, Samy, Abdallah M., Saravanan, Aswini , Sarfo, Jacob Owusu, Sarode, Gargi Sachin, Sarode, Sachin C., Sathian, Brijesh, Far, Mehrdad Savabi, Schlaich, Markus P., Schuermans, Art, Sejben, Anita, Semreen, Mohammad H., Senol, Yigit Can, Sessa, Francesco, Sewor, Christian , Seylani, Allen, Shahrahmani, Fatemeh, Shahwan, Moyad Jamal, Sham, Sunder, Shan, Dan, Sharifan, Amin , Sharma, Kamal, Sharma, Ravi Kumar, Sharma, Ujjawal , Shehzadi, Somia , Shetty, Mahabalesh, Shetty, Pavanchand H, Shi, Fanchao , Shi, Huizhong , Shi, Yongfeng, Shiri, Rahman , Shittu, Aminu, Shiue, Ivy, Shoaib, Ambreen, Shool, Sina, Shorofi, Seyed Afshin, Shuval, Kerem, Sia, Ching-Hui, Silva, Luís Manuel Lopes Rodrigues, Singh, Amit, Singh, Baljinder, Singh, Harmanjit, Singh, Harpreet, Singh, Lucky, Singh, Paramdeep, Singh, Siddharth , Singh, Sunil Kumar, Singh, Surjit, Singh, Vanshika , Sinha, Mukesh Kumar, Skryabin, Valentin Yurievich, Sokhal, Balamrit Singh , Sood, Prashant , Soraneh, Soroush , Sorensen, Reed J D , Srivastav, Prateek , Stanikzai, Muhammad Haroon , Starodubova, Antonina V., Stubbs, Peter, Suhag, Alisha, Sulaiman, Sahabi K., Odidi, Muritala Suleiman, Sulistiyorini, Desy , Sun, Jing , Sun, Zhong, Szarpak, Lukasz, Ty, Sree Sudha, Damavandi, Payam Tabaee, Tabatabaei, Seyyed Mohammad, Tabatabai, Shima, Tagiisuran, Balamurugan, Ali, Eman Taha Osman, Soodejani, Moslem Taheri, Taiba, Jabeen, Tajabadi, Shima, Talic, Stella, Talukder, Ashis, Adugna, Dessalegn Tamiru, Tampa, Mircea, Tan, Jianye, Tanabayeva, Dariga, Tanashat, Mohammad , Tang, Jiahao , Tantisattamo, Ekamol, Tariq, Saba, Temsah, Reem, Teramoto, Masayuki, Tesfamariam, Wegen Beyene , Tewari, Jay , Thakar, Vidhi, Thangavelu, Lakshmi, Tharwat, Ismaeel, Thiruvengadam, Muthu , Thomas, Nikhil Kenny, Ticoalu, Jansje Henny Vera, Tiwari, Krishna, Tleshev, Madi, Tonelli, Marcello, Topór-Mądry, Roman , Touvier, Mathilde, Tovani-Palone, Marcos Roberto, Tran, An Thien, Tran, Thang Huu, Duc, Nguyen Tran Minh , Tricò, Domenico , Tse, Gary, Tseriotis, Vasilis-Spyridon, Tualeka, Abdul Rohim , Tye, Sok Cin , Ullah, Riaz, Umair, Muhammad, Umar, Lawan , Ozsahin, Dilber Uzun, Uzunçıbuk, Hande, Vaithinathan, Asokan Govindaraj , Vakili, Omid , Eynde, Jef Van den, Varghese, Joe, Vellingiri, Balachandar, Verma, Poonam, Villalobos-Daniel, Victor E., Vlassov, Vasily, Wang, Nelson, Wang, Qingzhi, Wang, Wanzhou, Wang, Wei, Wang, Yanzhong, Wang, Zhihua, Wani, Tanveer A.A., Wei, Melissa Y., Weintraub, Robert G., Wibowo, Yohanes Cakrapradipta, Wickramasinghe, Dakshitha Praneeth, Wickramasinghe, Nuwan Darshana, Witts, William Kwame , Wonde, Tewodros Eshete , Wongsin, Utoomporn , Wu, Peng, Xiao, Guangqin, Xie, Wanqing , Xu, Suowen, Xu, Wanqing, Yadav, Vikas , Yahoo, Saba, Yang, Hanwen, Yano, Yuichiro , Yao, Haiqiang , Yarahmadi, Amir, Yin, Dehui , Yismaw, Yazachew Engida, Yon, Dong Keon, Yu, Chuanhua, Yu, Elaine A., Yu, Hairui , Yu, Yong , Yuan, Quan, Zafar, Mubashir , Zaghampour, Manijeh, Zamora, Nelson, Zanghì, Aurora , Zargar, Seema , Zeariya, Mohammed G M, Zeru, Eyael M, Zhang, Beijian, Zhang, Hanyu, Zhang, Julio Min Fei, Zhang, Yunquan, Zhang, Zhichang, Zhanuzakov, Murat , Zhao, Zhongyi, Zheng, Ming‐Hua , Zhong, Anthony , Zhong, Claire Chenwen, Zhou, Hao, Zhou, Jiayan, Zhou, Xiao-Dong, Zhu, Zhengyang , Zhumagaliuly, Abzal, Zitoun, Osama A. , Zoghi, Ghazal , Zoromba, Mohamed Ali, Zumla, Alimuddin, Zyoud, Sa’ed H., Hay, Simon I., Mokdad, Ali H., Murray, Christopher J. L., Roth, Gregory A., Sun, Zhong , Hay, Simon I , Roever, Leonardo , Krishan, Kewal , Moni, Mohammad Ali , Buendía, Jefferson Antonio , Badar, Muhammad , Wickramasinghe, Nuwan Darshana , Nassar, Mahmoud , Dewan, Syed Masudur Rahman , Naik, Ganesh R. , Wang, Yanzhong , Rath, Shree , Karakasis, Paschalis , Zheng, Ming-Hua , Taiba, Jabeen , Razo, Christian , DeCleene, Nicole K., LeGrand, Kate E , Abaraogu, Ukachukwu Okoroafor , ElHafeez, Samar Abd , Abdelmasseh, Michael , Abdelnabi, Mahmoud , Abd‐Elsalam, Sherief , Elshenawy, Rasha Abdelsalam , Abdelwahab, Siddig İbrahim , Abdolizadeh, Ali , Abdollahi, Arash, Abdoun, Meriem , Abdrabou, Mostafa M. , Abdulah, Deldar Morad , Abdullahi, Auwal , Shenkut, Melese, Abiodun, Olugbenga Olusola , Abiodun, Olumide A , Abohashem, Shady , Abtahi, Dariush , Farha, Rana Kamal Abu , Abubakar, Bilyaminu , Abuhelwa, Ahmad Y. , Abukhadijah, Hana J , Aburuz, Salahdein , Adamu, Nuhu Lawan , Adane, Mesafint Molla , Addo, Isaac Yeboah , Adedokun, Kamoru Ademola , Adekola, Saheed Ayodeji, Adesina, Miracle Ayomikun , Adisu, Molalign Aligaz , Adnan, Mohd , Afoakwah, Clifford , Afolabi, Aanuoluwapo Adeyimika, Afrifa‐Yamoah, Ebenezer , Afzal, Saira , Agordoh, Percival Delali , Ahmad, Aqeel , Ahmad, Khabir , Ahmad, Sajjad , Ahmed, Gasha Salih, Ahmed, Nesredin , Ajami, Marjan , Akhtar, Muhammad Nadeem , Akindele, Mukadas Oyeniran , Akkaif, Mohammed Ahmed , Akyea, Ralph Kwame , Zoubi, Mohammad Ahmmad Mahmoud Al, Alalwan, Tariq A. , Al‐Aly, Ziyad , Al-Amri, Issa Sulaiman , Alanzi, Turki Matar Khalaf, Al-Ashwal, Fahmi Y. , Al‐Azayzih, Ahmad , Al-Azzam, Sayer , Al-Bashaireh, Ahmad M. , ALBashtawy, Mohammed , Aleidi, Shereen M. , Algahtani, Fahad D. , AlHabib, Khalid F. , Ali, Abid , Ali, Asgar , Ali, Bassam R. , Al‐Iede, Montaha , Alif, Sheikh Mohammad , Alipour, Morteza, Al‐Jabi, Samah W. , Aljunid, Syed Mohamed , Alkubati, Sameer Abdulmalik , Almagharbeh, Wesam Taher , Almahmeed, Wael , Almazan, Joseph Uy , Alniss, Hasan Yaser , Alomari, Mahmoud A. , Alotaibi, Haifa F. , Alqahtani, Saleh A. , Alqudimat, Mohammad R. , Al-Qudimat, Ahmad Rajeh , Al‐Raddadi, Rajaa , Alsbou, Mohammed , Alshahrani, Najim Zafer , Al-Shami, Ali Salman , Altaf, Awais , Althobiani, Malik A , Alwafi, Hassan , Al‐Worafi, Yaser Mohammed , Aly, Hany Z. , Al‐Zalabani, Abdulmohsen H. , Alzoubi, Abdallah , Alzoubi, Karem Hasan , Amafah, Joy, Amin, Amr , Amini, Saeed, Amini‐Salehi, Ehsan , Amusa, Ganiyu , Ang, Song Peng , Anieto, Ebuka Miracle , Anil, Abhishek , Anjana, Dr. Prapti, Anvari, Saeid, Appati, Walter , Arabloo, Jalal , Arafat, Mosab , Areda, Demelash, Arefnezhad, Reza , Torre, Jorge Arias de la, Aripov, Timur , Arockiaraj, Jesu , Asdaq, Syed Mohammed Basheeruddin , Ashraf, Syed Amir , Ashraf, Tahira , Ataç, Ömer , Athar, Mohammad , Athari, Seyyed Shamsadin , Aurangzeb, Khursheed , Awan, Sana Javaid , Awol, Kemal Lemnuro, Awotidebe, Adedapo Wasiu , Aylı, Berrak Itır , Azarboo, Alireza , Aziz, Sadat Abdulla , Azzolino, Domenico , Babu, Abraham Samuel , Babu, Giridhara R. , Badiye, Ashish , Baghlaf, Khlood K , Baig, Atif Amin , Bakhshali, Mohamad Amin , Banach, Maciej , Banik, Palash Chandra , Barqawi, Hiba Jawdat , Barrow, Amadou , Barua, Lingkan , Bashir, Shahid , Bashiri, Azadeh , Bastan, Mohammad‐Mahdi , Bayih, Mulat Tirfie , Beeraka, Narasimha Murthy , Begum, Tahmina , Behera, Priyamadhaba , Behnam, Babak , Ramírez, Diana Fernanda Bejarano , Belo, Luı́s , Berihun, Abiye Assefa , Bhattacharjee, Priyadarshini , Bhatti, Gurjit Kaur , Bhatti, Jasvinder Singh , Biswas, Atanu , Biswas, Bijit , Bizzozero‐Peroni, Bruno , Bodur, Mahmut , Bogale, Sitotaw Kerie , Bohn, Lucimére , Boloor, Archith , Carvajal, Alejandro Botero , Boudalia, Sofiane , Bugiardini, Raffaele , Busch, Felix , Bustanji, Yasser, Campos, Luciana Aparecida , Catapano, Alberico Luigi , Cegolon, Luca , Cenko, Edina , Cerin, Ester , Chakraborty, Chiranjib , Chandika, Rama Mohan , Chandrasekar, Eeshwar K , Chandrasekaran, Baskaran , Chattu, Vijay Kumar , Chaudhary, Anis Ahmad , Chaudhuri, Sirshendu , Cheema, Asad Ali Ahmed , Chichagi, Fatemeh , Ching, Patrick R , Cho, William C.S., Choi, Dong‐Woo , Chong, Bryan , Chopra, Deepti , Chopra, Hitesh , Choudhari, Sonali Gajanan , Chu, Dinh‐Toi , Chukwu, Chidozie Williams , Chung, Sheng‐Chia , Chung, S. Y. , Cicero, Arrigo F.G. , Cosma, Claudia , Criqui, Michael H. , Dadras, Omid , Dai, Xiaochen , Dai, Zhaoli , Dalakoti, Mayank , D’Amico, Emanuele , Tesfa, Endalamaw , Danpanichkul, Pojsakorn , Darcho, Samuel Demissie , Davletov, Dimash , Davletov, Kairat , Dejenie, Tadesse Asmamaw , Bo’, Cristian Del , Delgado‐Enciso, Iván , Denova‐Gutiérrez, Edgar , Dergaa, Ismail , Dervišević, Emina , Devegowda, Devananda , Dewan, Syed Masudur Rahman , Dhimal, Meghnath , Dhungel, Bibha , Do, Thanh Chi, Phuong, Thao Huynh, Doshi, Ojas Prakashbhai , Doshi, Rajkumar , Dourado, Paulo Magno Martins , Dowou, Robert Kokou , Du, Mi , Duncan, Bruce Bartholow , Durães, André Rodrigues , Ebohon, Osamudiamen , Eftekhari, Behrad , Eladl, Mohamed Ahmed , Eldaboush, Ahmed , Elgendy, Islam Y. , Elhadi, Muhammed , El‐Huneidi, Waseem , Elmonem, Mohamed A. , Elmoselhi, Adel B. , Fabin, Natalia , Fadaka, Adewale Oluwaseun , Fagbamigbe, Adeniyi Francis , Fakorede, Sodiq , Fatima, Zareen , Fayaz, Mohammad , Fazylov, Timur, Fernández‐Jiménez, Rodrigo , Fischer, Florian, Fogacci, Federica , Foschi, Matteo , Gadanya, Muktar A., Gajdács, Márió , Galali, Yaseen , Ganesan, Balasankar , Gangachannaiah, Shivaprakash , Gašević, Danijela , Habtemichael, Mizan , Getacher, Lemma , Jolfayi, Amir Ghaffari , Ghamkhar, Arin, Ghazy, Ramy Mohamed , Ghimire, Sailaja, Ghith, Nermin , Gil, Artyom , Gill, Paramjit Singh , Gnedovskaya, Elena V. , Goh, Lay Hoon , Gohari, Kimiya, Golechha, Mahaveer , Goulart, Alessandra C. , Goyal, Aman , Grada, Ayman , Gu, Long , Gubari, Mohammed Ibrahim Mohialdeen , Guha, Avirup , Gunawardane, Damitha Asanga , Gupta, Rajeev , Gurgoglione, Filippo Luca , Guzmán-Esquivel, José , Guzmán-Muñoz, Eduardo , Haghtalab, Arian , Halder, Pritam , Hamdy, Nadia Μ. , Hammad, Eman A. , Hanif, Asif , Hanifi, Nasrin , Hankey, Graeme J. , Harsini, Sara , Hartmann, Phillipp , Hasan, Ikramul , Hashempur, Mohammad Hashem , Hassan, Amr , Hassan, Ibrahim Nagmeldin , Hayat, Khezar , Hezam, Kamal , Hiraike, Yuta , Holla, Ramesh , Hostiuc, Sorin , Htay, Mila Nu Nu , Huang, Junjie, Hushmandi, Kiavash , Hwang, Bing‐Fang , Ibitoye, Segun Emmanuel , Ibrahim, Khalid S. , Ibrayeva, Anel , Ikram, Jibran, Ilesanmi, Olayinka Stephen , Ilić, Irena , Ilić, Milena , Imodoye, Sikiru O. , Inbaraj, Leeberk Raja , Ionescu, Radu Tudor, Iqhrammullah, Muhammad , Irham, Lalu Muhammad , Ishaqui, Azfar Athar , Ismail, Nahlah Elkudssiah , Ismoldayev, Yerlan, Isola, Gaetano , Izquierdo‐Condoy, Juan S. , Jacob, Jaison , Jahanshahi, Ali , Jamal, Armaan , Jamali, Navid , James, Jerin , Jamshidi, Masoud , Jawaid, Talha, Jayasinghe, Yovanthi Anurangi , Jemal, Mohammed , Jeong, Seogsong , Jeswani, Bijay Mukesh , Jibat, Nathan Tolemariam , Jokar, Mohammad , Joó, Tamás , Joseph, Akaninyene Paul , Joseph, Mickaël Antoine , Joseph, Nitin , Joshi, Krupal , Jürisson, Mikk , K, Vaishali , Kakkar, Ashish Kumar , Kalani, Rizwan , Kalavani, Khalil , Kalra, Sanjay , Kamorudeen, Ramat T. , Kamyshnyi, Oleksandr , Kanaan, Saddam Fuad , Kanmodi, Kehinde Kazeem , Kantar, Rami S. , Kapoor, Neeti , Karajizadeh, Mehrdad , Karakasis, Paschalis , Karasneh, Reema A. , Kashoo, Faizan , Kashyap, Manoj Kumar , Kausar, Mohd Adnan , Kazemian, Sina , Kebede, Yabets Tesfaye , Kesse‐Guyot, Emmanuelle , Khademi, Reza , Khader, Yousef , Khajuria, Himanshu , Khaleel, Anas , Khalid, Sidra , Khalili, Anita , Khalili, Pantea , Khan, Maseer , Khan, Mohammad Idreesh , Khasbage, Sameer Uttamaro , Khatatbeh, Moawiah Mohammad , Khosla, Pavan , Khosravi, Sepehr , Kimokoti, Ruth W , Kısa, Adnan , Kishore, Ladli , Kivimäki, Mika , Kokkorakis, Michail , Kolahi, Ali‐Asghar , Kompani, Farzad , Kondybayeva, Аida , Korzh, Oleksii , Kostev, Karel , Laxminarayana, Sindhura Lakshmi Koulmane , Kua, Chong-Han , Kuddus, Mohammed , Kumar, Chandan , Kumar, G Anil , Kumar, Jogender , Kumar, Laksh , Kundu, Amartya , Kundu, Satyajit , Kunutsor, Setor K. , Kurniasari, Maria Dyah , Kytö, Ville , Lahariya, Chandrakant , Lakanova, Balzhan, Lantos, Tamás , Larebo, Yilma Markos , Lasrado, Savita , Lee�, HwaMin , Lee, Wei‐Chen , Leivaditis, Vasileios , Lenjisa, Jimma Likisa , Li, Ming‐Chieh , Li, Qiang , Li, Shaojie , Lim, Lee-Ling , Lodhi, Madeeha Shahzad , Lokunarangoda, Niroshan Chandrajith , López-Gil, José Francisco , Lorkowski, Stefan , Lucchetti, Giancarlo , Lui, Pauline Po Yee , Lv, Lei , Lytvyak, Ellina , Amin, Hawraz Ibrahim M. , Maffia, Pasquale , Magaña‐Gómez, Javier A. , Mahalleh, Mehrdad , Malik, Ahmad Azam , Malik, Tabarak , Malta, Déborah Carvalho , Mamand, Doste R. , Maniya, Muhammad Talha , Mannethodi, Kamaruddeen , Mansoor, Farheen, Mansourian, Marjan , Maqsood, Kaleem , Marateb, Hamid Reza , Marghani, Basma H. , Marino, Mirko , Martínez, Ramón , Martini, Daniela , Martini, Santi , Martorell, Miquel , März, Winfried , Marzouk, Sammer , Masi, Stefano , Mathur, Neeta , Matozinhos, Fernanda Penido , Mattiello, Rita , Mavrovounis, Georgios , McPhail, Steven , Mehto, Subhash , Meles, Hadush Negash , Menezes, Godfred Antony , Menon, Tara Pattilachan, Mensah, George A. , Merlino, Giovanni , Meštrović, Tomislav , Mettananda, Chamila Dinushi Kukulege , Mettananda, Sachith , Metwally, Mohamed M M, Mikrajab, Muhammad Agus, Minhas, Abdul Mannan Khan , Mittal, Madhukar , Mohamed, Nouh Saad , Ahmed, Khabab Abbasher Hussien Mohamed , Mohammad, Taj , Mohammadi, Abbas , Mohammadi, Mokhtar , Mohammadian-Hafshejani, Abdollah , Mohsen, Yazan , Shibabaw, Tewodros , Molokhia, Mariam , Monazzami, Amirabbas , Ghalibaf, AmirAli Moodi , Morovvati, Mahdis, Motappa, Rohith , Mozafar, Mehrdad , Mubarik, Sumaira , Muhammad, Jibran Sualeh , Munkhsaikhan, Yanjinlkham, Munshi, Anjana , Musa, Sani , Muthu, Sathish , Mwita, Julius Chacha , Myung, Woojae , Nainu, Firzan , Nargus, Shumaila , Nasrollahizadeh, Amir , Nassar, Mahmoud, Nauman, Javaid , Navaratna, Samidi Nirasha Kumari , Nawaiseh, Hala K. , Nayak, Biswa Prakash, Nega, Mulata Haile , Negash, Abigia Ashenafi , Negoi, Ionuţ , Abadi, Reza Nejad Shahrokh , Nematollahi, Mohammad Hadi , Nieddu, Luciano , Nketia, Richmond , Noubiap, Jean Jacques , Nri-Ezedi, Chisom Adaobi , Ntsekhe, Mpiko , Nugen, Fred , Oancea, Bogdan , Odat, Ramez M. , Oddi, Fabio Massimo , Oh, In‐Hwan , Okekunle, Akinkunmi Paul , Okonji, Osaretin Christabel , Olorukooba, Abdulhakeem Abayomi , Ong, Qi Chwen , Ordak, Michał , Orscelik, Atakan , Ortiz‐Prado, Esteban , Osuagwu, Uchechukwu Levi , Oumer, Abdu , Ouyahia, Amel , Özşahin, İlker , Padrón‐Monedero, Alicia , Padubidri, Jagadish Rao , Panos, Georgios D. , Papa, Mario Virgilio , Pardhan, Shahina , Passera, Roberto , Patel, Kunal Nitinkumar , Patel, Neel Navinkumar , Patel, Satyananda, Patil, Shankargouda, Patoulias, Dimitrios , Pattnaik, Snigdha, Toroudi, Hamidreza Pazoki, Pekarčíková, Jarmila , Peprah, Prince , Pereira, Gavin, Perico, Norberto , Perna, Simone , Petermann‐Rocha, Fanny , Pirnejad, Habibollah , Plotnikov, Evgenii, Poddighe, Dimitri , Poluru, Ramesh , Porntaveetus, Thantrira , Pradhan, Pranil Man Singh , Prasad, Manya , Prashant, Akila , Pugliese, Nicola Riccardo , Puvvula, Jagadeesh , Qiu, Jia-Yong , Radhakrishnan, Venkatraman, Raghav, Pankaja Raghav, Rahamon, Sheu Kadiri , Rahim, Hawbash Mohammed-Amin , Rahimi, Sajjad , Rahman, Muhammad Aziz , Raj, Jeffrey Pradeep , Raja, Adarsh , Rajendran, Judah , Rajput, Prashant , Ramadan, Mahmoud M. , Ramasamy, Chitra, Ramasamy, Shakthi Kumaran, Rashedi, Vahid , Rasouli‐Saravani, Ashkan , Rath, Shree , Rathi, Isha , Rathish, Devarajan , Rauniyar, Santosh Kumar , Rawassizadeh, Reza , Ray, Asit , Redwan, Elrashdy M , Rehman, Najeeb Ur , Remuzzi, Giuseppe , Rezaei, Nazila , Romadlon, Debby Syahru , Romoli, Michele , Rony, Moustaq Karim Khan , Ross, Allen Guy , Roy, Sharmistha , Roy, Shubhanjali , Russo, Michele , Saber-Ayad, Maha Mohamed , Sabet, Cameron John , Sadarangani, Kabir P. , Rafiei, Seyed Kiarash Sadat , Saddique, Muhammad Nabeel , Sadee, Bashdar Abuzed , Sadeghi, Masoumeh , Sadek, Bassem Shaban , Sadr, Hossein, Saeb, Mohammad Reza , Saeed, Mοhd , Saeedi, Maryam , Saghazadeh, Amene , Sagoe, Dominic , Sah, Ashok Kumar , Sharif‐Askari, Fatemeh Saheb , Sahebkar, Amirhossein , Sajadi, S. Mohammad, Sajid, Mirza Rizwan , Saki, Morteza , Sakshaug, Joseph W. , Salami, Afeez Abolarinwa , Saleem, Rahman Shah Zaib , Salihu, Abubakar Tijjani , Salimi, Sohrab , Samargandy, Saad J. , Samodra, Yoseph Leonardo , Samy, Abdallah M., Sarfo, Jacob Owusu , Sarmadi, Mohammad , Sarode, Gargi Sachin , Sassano, Michele , Sathian, Brijesh , Narayanan, Mukesh Kumar Sathya , Schlaich, Markus P. , Schuermans, Art , Schwarz, Ghil , Sejben, Anita , Selvaraj, Siddharthan , Semreen, Mohammad H. , Şenol, Yiğit Can , Şerban, Dragoş , Sethi, Yashendra , Setiawan, Christianus Heru , Shahid, Samiah , Shahini, Endrit , Shahrahmani, Fatemeh, Shahwan, Moyad Jamal , Shamim, Muhammad Aaqib , Shamsi, Anas , Shan, Dan, Shanawaz, Mohd , Shannawaz, Mohammed , Sharif, Nadim , Sharma, Bhoopesh Kumar , Sharma, Bunty, Sharma, Manoj , Sharma, Vishal , Shastry, Shamee , Sheidaei, Ali , Shenoy, Rekha R. , Shimels, Tariku , Shittu, Aminu , Shoaib, Ambreen , Shool, Sina , Shrestha, Sunil , Shuval, Kerem , Sia, Ching‐Hui , Siddig, Emmanuel Edwar , Siddiqi, Ahmed Kamal , Siddiqua, Ayesha , Silva, Diego Augusto Santos , Simkhada, Padam Prasad , Singh, Amit Kumar, Singh, Baljinder, Singh, Harpreet, Singh, Jasvinder A. , Singh, Lucky, Singh, Poornima Suryanath , Singh, Puneetpal , Sinha, Mukesh Kumar , Sinha, Ratnesh , Skryabin, Valentin Yurievich , Sorrentino, Michele , Spartalis, Michael , Stachteas, Panagiotis , Владимировна, Стародубова Антонина, Straube, Sebastian , Stubbs, Peter W. , Su, Chen‐Yang , Subramaniyan, Vetriselvan , Suhag, Alisha , Sulaieva, Oksana , Sun, Jing , Swain, Chandan Kumar , Szarpak, Łukasz , Y, Sree Sudha T, Damavandi, Payam Tabaee , Tabarés‐Seisdedos, Rafael , Tabatabaeizadeh, Seyed‐Amir , Tabche, Celine , Tadele, Afework , Ali, Eman T. , Soodejani, Moslem Taheri , Tajabadi, Shima, Talic, Stella , Talukder, Ashis , Zadeh, Seyed Saeed Tamehri , Tampa, Mircea Ştefan , Tantisattamo, Ekamol , Tariku, Mengistie Kassahun , Tavangar, Seyed Mohammad , Tedla, Mebrahtu G. , Teramoto, Masayuki , Tesfu, Azimeraw Arega , Tharwat, Ismaeel, Tharwat, Samar , Thienemann, Friedrich , Tiruye, Tenaw Yimer , Tleshev, Madi, Tomo, Sojit , Tonelli, Marcello , Touvier, Mathilde , Tran, An Thien, Tran, Thang Huu, Tristan, Christopher Daniel , Tse, Gary , Tseriotis, Vasilis‐Spyridon , Udoakang, Aniefiok John , Ullah, Atta , Ullah, Saeed , Umair, Muhammad, Upadhya, Dinesh , Upadhyay, Era , Usman, Jibrin Sammani , Ozsahin, Dilber Uzun , Uzunçıbuk, Hande , Varghese, Joe , Vasankari, Tommi Juhani , Vellingiri, Balachandar , Venketasubramanian, Narayanaswamy , Verma, Akshaya Kumar , Villalobos-Daniel, Victor Eduardo , Wan, Jin‐Yi , Wang, Cong , Wang, Nelson , Wang, Shaopan , Wang, Shu , Wang, Youxin , Wani, Tanveer A. , Waqar, Ahmed Bilal , Weintraub, Robert G, Wibowo, Yohanes Cakrapradipta, Wicaksana, Anggi Lukman , Wickramasinghe, Dakshitha Praneeth , Wilandika, Angga , Xu, Site , Xu, Suowen , Xu, Xiaoyue , Yadegar, Amirhossein , Yahoo, Saba, Yamagishi, Kazumasa , Yaribeygi, Habib , Yesuf, Subah Abderehim , Yon, Dong Keon , Yonemoto, Naohiro , Yuan, Quan, Yuzbashian, Emad , Zamagni, Giulia , Zawiah, Mohammed , Zeariya, Mohammed G M, Zeru, Eyael M, Zhang, Casper J. P. , Zhong, Claire Chenwen , Zhou, Xiao-Dong, Zhumagaliuly, Abzal , Zoromba, Mohamed Ali , Zumla, Alimuddin I. , Zyoud, Ahed H. , Zyoud, Shaher H. , Mokdad, Ali H. , Murray, Christopher J. L., Roth, Gregory A., Kheirallah, Khalid Ahmed , Saad, Aly M A , Sadeghi, Erfan

Mayo Clinic

JAMA | July 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.8628 | PMID 42525403 Get It

Importance Elevated low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for cardiovascular disease, the leading cause of premature death worldwide. Assessing the LDL-C–related burden is critical for guiding prevention and treatment strategies. Objectives To estimate the global, regional, and national burden of ischemic heart disease and ischemic stroke attributable to elevated LDL-C (relative to 35-54 mg/dL) from 1990 to 2023 and to quantify the contributions of population growth, aging, risk-deleted burden, and exposure changes to burden trends. Design, Setting, and Population This comparative risk assessment, part of the Global Burden of Disease Study 2023, estimated population-level LDL-C exposure and associated health loss in 204 countries and territories. Mean LDL-C levels were estimated using spatiotemporal gaussian process regression based on 806 studies across 161 countries. Relative risks were derived from meta-analyses of 38 randomized clinical trials. Population-attributable fractions for deaths and disability-adjusted life-years (DALYs) were estimated by age and sex for adults aged 25 years or older from 1990 to 2023, with 95% uncertainty intervals. Exposure Population-level LDL-C concentrations. Main Outcomes and Measures Population-attributable fractions, counts, and rates (all ages and age standardized per 100 000) of LDL-C–attributable deaths and DALYs from ischemic heart disease and ischemic stroke, with uncertainty intervals. Results In 2023, elevated LDL-C accounted for 3.6 million deaths (95% uncertainty interval, 2.2-5.4 million; 6.0% of global mortality) and 90.7 million DALYs (95% uncertainty interval, 58.9-123.3 million; 3.2% of DALYs). Although global all-ages rates remained stable, age-standardized death and DALY rates decreased by 45.6% and 39.5%, respectively, since 1990. In 2023, age-standardized LDL-C–attributable DALY rates were highest in Eastern Europe and lowest in high-income Asia-Pacific. One-third of the global LDL-C burden occurred in India and China. Population growth and aging drove the increasing burden, with notable regional disparities in LDL-C exposure and risk-deleted DALY rates shifting toward middle-sociodemographic settings. Conclusions and Relevance Despite declining age-standardized rates, the absolute LDL-C burden has increased since 1990 due to demographic changes and has shifted toward middle-sociodemographic countries. Measurement and surveillance gaps persist. Strengthened prevention, diagnosis, and treatment access strategies are essential to mitigate the health burden of LDL-C.
Neonatal Survival After Serial Amnioinfusions for Anhydramnios Due to Fetal Kidney Failure
Baschat, Ahmet A., Johnson, Anthony , Blumenfeld, Yair J., Schenone, Mauro H., Gebb, Juliana , Moldenhauer, Julie S., Zaretsky, Michael V. , Chmait, Ramen H., Gonzalez, Juan M., Rl, Miller, Krispin, Eyal , Shamshirsaz, A H A, Bligard, Katherine H. , Kalan, Amanda, Cortes, Magdalena Sanz, Bendel-Stenzel, Ellen, Menon, Shina , Wong, Cynthia, Kwak, Cecilia, Gallup, J Y, McKenna, Kristin, Marron, L, Tran, Cheryl L. , Behrendt, Nicholas, Galan, Henry L. , Samuels, Joshua, Swinford, Rita, Rosner, Mara, Kush, Michelle L, Nasr, Isam, Vasu, Samhita , Boss, Renee D. , Jelin, Angie C., Thompson, Richard E. , Davis, Jonathan M. , Warren, Daniel , Atkinson, Meredith A. , Gebb, Juliana S , Menon, Shina , Miller, Jena L. , Baschat, Ahmet , Blumenfeld, Yair J. , Schenone, Mauro H , Moldenhauer, Julie S. , Chmait, Ramen H. , Gonzalez, Juan, Cortes, Magdalena Sanz , Moon‐Grady, Anita J. , Bendel‐Stenzel, Ellen , Grimm, Paul, Marron, Leah, Hanna, Christian , Swinford, Rita D., Keiser, Amaris , Rosner, Mara , Nasr, Isam W. , Boss, Renee Denise , Jelin, Angie Child , Hanley, Daniel F.

Mayo Clinic

JAMA | July 1, 2026 | Volume: 336 | Issue: 6 | Pages: 473

10.1001/jama.2026.8568 | PMID 42384373 Get It

Importance Anhydramnios from fetal kidney failure causes lethal pulmonary hypoplasia. Serial amnioinfusions have shown promise in mitigating pulmonary disease from bilateral renal agenesis, but efficacy and safety for other causes of fetal kidney failure are unproven. Objective To assess the efficacy of serial amnioinfusions initiated before 26 weeks’ gestation to mitigate lethal pulmonary hypoplasia in cases of anhydramnios due to fetal kidney failure. Design, Setting, and Participants Prospective, nonrandomized clinical trial conducted at 13 US fetal therapy centers from December 2018 to February 2025. Outcomes for maternal-fetal pairs with anhydramnios before 22 weeks’ gestation due to fetal kidney failure without bilateral renal agenesis are reported; data collection for surviving infants continued until February 13, 2026. Exposure Thirty-two participants underwent serial amnioinfusions with isotonic fluid beginning before 26 weeks’ gestation. Main Outcomes and Measures The primary end point was neonatal survival for 14 days or longer with dialysis access placement. Secondary outcome measures of survival to discharge home and kidney transplant are reported. Results Twenty-nine of 32 participants (91%) had a live birth, with a median (IQR) gestational age at delivery of 34 weeks 1 day (31 weeks 5 days to 34 weeks 6 days). All participants delivered before 37 weeks’ gestation. No unexpected serious maternal adverse events occurred, and the most common maternal complications were preterm prelabor rupture of membranes in 19 participants (56%) and chorioamniotic separation in 10 (29%). The primary outcome occurred in 19 (65.5%) of 29 live-born neonates (95% CI, 45.7%-82.1%). Factors associated with survival to the primary outcome included receiving more amnioinfusions (median [IQR], 14 [9-18] in survivors vs 7 [4-11] in nonsurvivors; P = .01), longer time interval from first amnioinfusion to preterm prelabor rupture of membranes (63.5 [60.5-74.5] days in survivors vs 29.0 [22.0-56.0] days in nonsurvivors; P = .01), gestational age greater than 32 weeks (79% of survivors vs 38% of nonsurvivors; P = .03), and higher birth weight (2029 [1770-2250] g in survivors vs 1635 [1185-1915] g in nonsurvivors; P = .01). Fourteen live-born infants (48%) survived to hospital discharge at a median (IQR) age of 4.7 (3.4-5.7) months. Of the 11 infants surviving to date, 7 (64%) have undergone kidney transplant between ages 2 years to 5 years. Conclusions and Relevance Serial amnioinfusions mitigated lethal pulmonary hypoplasia in neonates with anhydramnios due to fetal kidney failure. Significant neonatal morbidity and mortality independent of early lung function was noted. Factors associated with survival were consistent with the Renal Anhydramnios Fetal Therapy trial’s bilateral renal agenesis cohort, suggesting common mechanistic pathways for mitigating pulmonary hypoplasia. Trial Registration ClinicalTrials.gov Identifier: NCT03101891
Clinical Outcomes of Pre-Transplant Cardiac Prehabilitation in the ICU on Impella 5.5
Jena, Anek , Pareek, Aayushi , Bateh, Said, Faiz, Saleem, Olaizola, Gustavo , Huespe, Ivan, Bauque, Susana, Prado, Eduardo, Hanson, Abby, Sujanyal, Saurabh, Haney, John, Amoroso, Penny, Vilela, Sara, BRITTON, KIMBERLY, Matos, Nikki, Ojard, Michelle, Kiley, Sean, Hannon, Rachel, Moreno, Juan Carlos Leoni, Thomas, Mathew, Sareyyüpoğlu, Başar , Sura, Lydia, Worsowicz, Greg, Lyle, M., Patel, Parag, Sanghavi, Devang, Shapiro, Anna, Bateh, Said , Saleem, Faiz , Prado, Eduardo , Haney, J., Vilela, Sara , Matos, Nikki , Hannon, Rachel, Thomas, Mathew , Worsowicz, Gregory M., Lyle, Melissa , Patel, P S, Franco, Pablo Moreno , Sanghavi, Devang , Shapiro, Anna

Mayo Clinic

ASAIO Journal | June 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mat.0000000000002748 | PMID 42241078 Get It

Prehabilitation with Impella 5.5 offers hemodynamic support while allowing early mobilization, yet its overall effect on post-transplant recovery remains unclear. The aim was to assess recovery during Impella 5.5–supported prehabilitation and determine its association with early post-heart transplant outcomes, including a potential dose–response relationship with ambulatory activity. We conducted a single-center retrospective cohort study of adults bridged to transplant with Impella 5.5 between April 1, 2022 and September 30, 2024. Daily walking distance, recorded by nursing staff, served as the intervention. Primary outcome was postoperative hospital length of stay (LOS); the secondary outcome was time to extubation. Fine–Gray competing-risk models, adjusted for age, Sequential Organ Failure Assessment (SOFA) score, New York Heart Association (NYHA) class, and days of Impella support, assessed associations. Longitudinal recovery trajectories were analyzed with linear mixed-effects models incorporating restricted cubic splines. Among 82 eligible patients, 65 met the inclusion criteria. Patients who walked farther during Impella 5.5 support in the intensive care unit (ICU) had shorter hospital stays and were taken off the ventilator sooner after transplantation. The overall recovery peaked during the first 2–3 weeks of support, with smaller recovery thereafter, indicating that most functional recovery occurred early during prehabilitation.
Impact of prior treatment setting on the efficacy of rucaparib vs physician’s choice in BRCA -mutated castration-resistant prostate cancer (mCRPC) in TRITON3.
Sridhar, Srikala S., Fizazi, Karim Olivier, Chowdhury, Simon, Ryan, Charles J. , Alonso-Gordoa, Teresa, Arranz, José Ángel, Birtle, Alison , Byard, Ian, Carrozza, Francesco , Giorgi, Ugo De, Duran, Ignacio, Goeminne, Jean-charles, Goldfischer, Evan R., Despain, Darrin, Craib, Marcia, Lindberg, Henriette , Sridhar, Srikala S , Fizazi, Karim , Bryce, Alan H. , Chowdhury, Simon, Alonso‐Gordoa, Teresa , Giorgi, Ugo De , Durán, Ignacio , Goeminne, Jean‐Charles, Goldfischer, Evan R., Grimm, Marc‐Oliver , Despain, Darrin , Craib, Marcia L.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 5054-5054

10.1200/jco.2026.44.16_suppl.5054 Get It

5054 Background: Rucaparib significantly improved radiographic progression-free survival (rPFS) versus physician’s choice of docetaxel or an androgen-receptor pathway inhibitor (ARPI) (abiraterone or enzalutamide) in men with BRCA mutations who were chemotherapy-naïve in the mCRPC setting and had received one prior ARPI in the phase 3 TRITON3 trial (NCT02975934). This post-hoc analysis evaluated whether the timing of prior ARPI therapy impacted the efficacy of rucaparib. Methods: Patients were randomized 2:1 to rucaparib (600 mg BID) or physician’s choice of docetaxel or ARPI, after progression on 1 prior second-generation ARPI in any setting. The primary endpoint was rPFS. Outcomes were analyzed according to whether patients received the prior ARPI in the metastatic castration sensitive (mCSPC) or castration resistant (mCRPC) setting. Data cutoff was August 25, 2022. Results: Of the 302 BRCA1/2 patients, 68 received prior ARPI in the mCSPC setting (42 rucaparib; 26 physician’s choice) and 234 in the mCRPC setting (159 rucaparib; 75 physician’s choice). Baseline characteristics were generally similar. Prior treatments in the mCSPC and mCRPC groups, respectively, included abiraterone (73.5% vs 53.0%), enzalutamide (29.4% vs 48.3%), and docetaxel (17.6% vs 24.8%). Median rPFS favored rucaparib over physician’s choice in both groups (mCSPC: 13.6 vs 8.2 months; HR 0.60 [95% CI, 0.32–1.15]; mCRPC: 11.2 vs 5.8 months; HR 0.43 [95% CI, 0.30–0.61]). Median OS was similar between treatments in both settings (mCSPC: 23.2 vs 21.7 months; HR 0.81 [95% CI, 0.47–1.41]; mCRPC: 23.2 vs 21.0 months; HR 0.91 [95% CI, 0.66–1.25]). Treatment-related adverse events occurred at comparable rates (89.6% vs 86.1%). Conclusions: Rucaparib demonstrated efficacy in patients with BRCA-mutated mCRPC, regardless of whether prior ARPI was administered in the mCSPC or mCRPC setting. Clinical trial information: NCT02975934 .
zA58-04 Rising Mortality From Pulmonary Hypertension in the Aging US Population: A CDC Wonder Database Analysis From 1999 to 2020
Singh, A, Singh, A, Shah, S H, Jena, A, Khanal, S, Shah, S H, Jena, A, Khanal, S

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5509 Get It

Abstract Rationale Pulmonary hypertension (PH) is a progressive, heterogeneous group of disorders leading to right heart failure and death. Despite advances in management, population-level mortality trends among older adults remain poorly characterized. Understanding these long-term trends is essential for designing equitable, population based interventions. Methods We analyzed mortality data for adults aged 65 years and above using the CDC WONDER database from 1999 to 2020. PH related deaths were identified using ICD 10 codes (I27.0, I27.2,I27.8,I27.9). Age adjusted mortality rates (AAMR) per 100,000 population were calculated and stratified by sex, race and comorbid conditions including hypertension, type 2 diabetes mellitus and congestive heart failure. Temporal trends were evaluated using joinpoint analysis to estimate average annual percent change (AAPC) with corresponding p-values. Results From 1999 to 2020, a total of 141,243 PH related deaths occurred among US adults aged 65 years and above, corresponding to an overall AAMR of 9.1 per 100,000 (95% CI, 8.9-9.3). Annual mortality increased from 5.2 in 1999 to 13.4 in 2020, a 2.6-fold rise (AAPC +3.8%; p < 0.001). Females accounted for 63.7% of all PH deaths and had higher mortality than males (10.8 vs 7.2 per 100,000). Black individuals experienced the highest mortality (12.5 per 100,000), exceeding rates among White (8.7) and Hispanic (7.9) counterparts. The proportion of PH deaths associated with cardiometabolic comorbidities rose substantially, with the largest annual increase seen in PH with coexisting HTN (+4.9% per year), followed by CHF (+4.6%) and T2DM (+4.1%). Conclusions Despite therapeutic progress, overall PH related mortality among older U.S. adults rose significantly from 1999 to 2020. Persistent sex and race based disparities highlight inequities in disease burden and access to care. The increasing coexistence of cardiometabolic comorbidities suggests evolving pathophysiology and emphasizes the need for prevention focused, multidisciplinary strategies. Future work should explore modifiable risk factors and healthcare system determinants driving these trends to inform targeted public health and policy interventions. This abstract is funded by: None
C23-22 Catheter Directed Thrombolysis Versus Systemic Therapy in Pulmonary Embolism: A Decade of Experience From the National Inpatient Sample (2010-2021)
Singh, A, Singh, A, Shah, S H, Jena, A, Khanal, S, Jena, A

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.3486 Get It

Abstract Rationale High and intermediate risk pulmonary embolism (PE) contributes significantly to in hospital morbidity and 5-10% of in hospital deaths. Thrombolytic therapy either via systemic intravenous tissue plasminogen activator (IV-tPA) or catheter directed thrombolysis (CDT) remains central to management, however, comparative national data on utilization and outcomes of thrombolytic therapy for PE remain limited. Methods Using the National Inpatient Sample data from 2010 to 2021, adult hospitalizations for acute PE were identified using ICD 9 code 415.1 and ICD 10 code I26. Cases receiving IV-tPA or CDT were identified using procedural codes. Temporal trends, in-hospital mortality, length of stay (LOS) and complications were compared between treatment groups using weighted analyses. Results Among 1,940,718 hospitalizations with acute pulmonary embolism, the use of thrombolytic therapy increased from 2010 to 2021 for both systemic intravenous tissue plasminogen activator (IV-tPA) and catheter-directed thrombolysis (CDT). Utilization of IV-tPA rose from 1.8% to 2.%, while CDT increased from 1.4% to 3.9%. Compared to IV-tPA, patients treated with CDT were more likely to be older (42.7% vs 39.3% were aged 65 years or above) and male (50.8% vs 48.7%). CDT was associated with significantly lower in hospital mortality (6.7% versus 11.1%, p < 0.01), shorter median length of stay (5 versus 6 days, p < 0.01) and fewer discharges to facilities (13.7% versus 19.4 %, p < 0.01). Rates of major complications were lower in the CDT group, including intracranial hemorrhage (0.4% versus 1.2%), cardiac arrest (1.7% versus 7.3%), myocardial infarction (4.7% versus 5.1%) and need for mechanical ventilation (6.7% versus 16.1%). However, use of extracorporeal membrane oxygenation (0.7% versus 0.2 %) and surgical embolectomy (1.2% versus 0.7%) was higher among CDT patients. Conclusions From 2010 to 2021, utilization of thrombolytic therapy, particularly catheter-directed techniques increased among PE hospitalizations. CDT was associated with lower in hospital mortality, shorter stays and fewer complications compared to systemic IV-tPA. These findings support the expanding role of catheter based interventions as a preferred therapeutic approach for patients with high and intermediate risk pulmonary embolism. Further prospective studies are warranted to confirm long term outcomes and optimize patient selection for CDT. This abstract is funded by: None
C71-16 Diagnostic Accuracy of Genomic Classifier in Patients With Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Studies Published up to 2025
Singh, A, Singh, A, Jena, A, Phadke, R, Paudel, E O’Shea, PAUDEL, ERIN E O'SHEA

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2784 Get It

Abstract Rationale The diagnosis of interstitial lung disease (ILD) requires a multidisciplinary discussion (MDD), in which high-resolution computed tomography (HRCT) and histopathology play key roles. Genomic classifiers have recently been introduced for clinical use, in which lung tissue obtained via transbronchial forceps biopsy undergoes whole-transcriptome RNA sequencing followed by gene expression analysis. These molecular tools are particularly valuable in establishing a diagnosis of idiopathic pulmonary fibrosis (IPF) in patients without a definite usual interstitial pneumonia (UIP) pattern on imaging. Although genomic classifiers are increasingly utilized in clinical practice, data on their diagnostic performance continue to evolve, warranting an updated analysis of the current evidence. Methods A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. Comprehensive search of PubMed, MEDLINE, Embase, Scopus and the Cochrane Library were performed through October 2025 using predefined terms including “genomic classifier,” “Envisia,” “UIP,” and “interstitial lung disease.” Eligible studies were which enrolled adult patients with ILD of uncertain etiology in whom genomic classifiers were compared with histopathologic or MDD based reference standards. True positive, false positive, false negative, and true negative data were extracted to calculate pooled estimates of sensitivity, specificity and the area under the receiver-operating characteristic curve (AUROC) using a random-effects bivariate model. Results Six studies comprising 347 patients met inclusion criteria, with sample sizes ranging from 24 to 98 participants. Across studies, sensitivity ranged from 59% to 85% and specificity from 75% to 100%. The pooled sensitivity was 68% (95% CI, 60-76%; P < 0.001) and specificity 77% (95% CI, 70-85%; P < 0.001), with an estimated AUROC of 0.73 (95% CI, 0.65-0.81) indicating discriminative performance. In two studies evaluating clinical impact, incorporation of genomic classifier data into MDD increased diagnostic confidence in ILD subtyping by 30-50%. No major adverse events related to transbronchial tissue acquisition were reported. Conclusions Genomic classifiers represent a promising, less invasive adjunct for identifying UIP patterns in ILD, demonstrating good overall diagnostic accuracy. Incorporating classifier results within MDD frameworks enhances diagnostic confidence and may reduce the need for surgical lung biopsy in appropriately selected patients. However, small study sizes, potential funding bias and limited accessibility highlight the need for larger, independently conducted prospective studies to further define their role in future IPF diagnostic algorithms. This abstract is funded by: None
B47-35 A Silent Complication: Rare Case of Inhaled Tobramycin Associated Ototoxicity in Patient With Preserved Renal Function
Singh, A, Singh, A, Phadke, R, Surana, A, Jena, A, Bhattacharya, R, Martin, K B, SURANA, ARIHANT, Martin, Kevin Braun

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.1260 Get It

Abstract Introduction Aminoglycoside antibiotics are well known to cause cochlear and vestibular toxicity when used systemically. Inhaled tobramycin was developed to reduce systemic exposure and is considered safer with only rare reports of ototoxicity have been reported in patients with renal dysfunction. We describe a case of bilateral sensorineural hearing loss (SNHL) and tinnitus associated with inhaled tobramycin in a patient without renal impairment, emphasizing that even inhaled formulations can induce significant auditory toxicity in susceptible individuals. Case A 85 year old woman with Sjogren’s related interstitial lung disease and bronchiectasis who was chronically colonized by Pseudomonas aeruginosa was treated with inhaled tobramycin for recurrent infections. She had normal renal function and no prior aminoglycoside exposure. After approximately three months of inhaled therapy, she noted progressive bilateral hearing decline and high pitched tinnitus without vertigo or otalgia. Physical examination revealed clear ear canals and intact tympanic membranes. Baseline audiometry one year ago had demonstrated mild to moderately-severe bilateral SNHL. Repeat testing after tobramycin exposure showed worsening thresholds and reduced word recognition bilaterally. MRI of the brain and internal auditory canals was unremarkable. Serum creatinine remained normal throughout treatment. Inhaled tobramycin was discontinued, after which hearing loss stabilized. No further progression was observed on follow-up audiometry. Discussion Although systemic absorption from inhaled tobramycin is typically low, elderly and low-body-weight patients may accumulate sufficient serum levels to cause cochlear injury. Mechanisms include reactive oxygen species mediated hair cell toxicity and possible genetic susceptibility involving the mitochondrial 12S rRNA mutation. Prior reports of vestibulotoxicity and cochleotoxicity from inhaled tobramycin primarily involved patients with renal dysfunction, however, this case report demonstrates that toxicity can occur despite preserved renal function. Clinicians should maintain vigilance for otologic symptoms in patients receiving inhaled aminoglycosides. Baseline and periodic audiometric monitoring should be incorporated into chronic treatment protocols. This abstract is funded by: None
Ketamine Use in Critically Ill Patients: Insights into Depressive Symptoms and Hemodynamic Changes
Patel, Vrutti , Sujanyal, Saurabh Ashok , Raavi, Lekhya , Blumenfeld, Sophia G. , Saleem, Faiz , Bateh, Said , Hanson, Abby , Jena, Anek , Isha, Shahin , Pietrzak, Katheleen A. Rottman, Ojard, Michelle, Shah, Sadia Z. , Sanghavi, Devang , Anna, Shapiro, Sujanyal, Saurabh , Rottman Pietrzak, Katheleen A, Ojard, Michelle M , Huespe, Ivan Alfredo , Moreno Franco, Pablo , Edwards, Michael A. , Chauhan, Mohit , Sanghavi, Devang K , Shahin, Isha , Kunze, Katie L. , Johnson, Patrick W. , Pietrzak, Katheleen A., Huespe, Iván , Franco, Pablo Moreno , Chauhan, Mohit

Mayo Clinic

Journal of Intensive Care Medicine | April 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/08850666261438474 | PMID 41989186 Get It

Background Ketamine has demonstrated efficacy in treatment-resistant depression, primarily in psychiatric or outpatient populations. Its use in ICU patients remains underexplored, with limited data beyond case reports and small series. This study evaluated the association between subanesthetic ketamine infusions and improvement in depressive symptoms and hemodynamic changes in ICU patients. Methods We conducted a retrospective study of adults admitted to the ICU who received IV ketamine (0.3-0.75 mg/kg over 40 min on three consecutive days) for depressive symptoms. Changes in depressive symptoms were assessed using routine clinical documentation by physicians, nurses, and occupational and physical therapists. Hemodynamic parameters (blood pressure and heart rate) were recorded before and up to 120 min after infusion. The primary outcome was to evaluate depressive symptoms while the secondary outcome was to assess hemodynamic changes post transfusion. Results Thirty-four patients met criteria, including 18 solid organ transplant recipients. Median age was 59 years; 61.8% were male. Ketamine was associated with improvement in apparent sadness (90.0% vs 52.2%, P < .05) and reported sadness (95.0% vs 59.1%, P < .05). In transplant recipients, improvement in apparent sadness remained significant (80.0% vs 41.7%, P < .05). Hemodynamic parameters remained stable; heart rate increased transiently at 15-30 min post-infusion, returning to baseline by 60-90 min. Adverse effects observed were anxiety (12.5%), restlessness and/or agitation (10.4%), and dissociation (8.16%). Conclusion Subanesthetic ketamine improved specific depressive symptoms in critically ill ICU patients without significant hemodynamic instability. These findings support its potential as a rapid-acting antidepressant in the ICU, warranting further prospective trials.
816: NEUROLOGICAL OUTCOMES FOLLOWING ECPR VS CONVENTIONAL CPR: SYSTEMATIC REVIEW AND META-ANALYSIS
Jena, Anek , Singh, Aditya, Merchant, Kiran, Banker, Himanshi , Sarangi, Swapna , Shah, Syed Hamza, Antar, Mohamed, Ferreira, Esteban Rodriguez, Rios, Anthony Navarrete, Bordini, Joao

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001185260.74333.66 Get It